Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-02-02
2008-11-25
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C536S023100, C435S235100
Reexamination Certificate
active
07456251
ABSTRACT:
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
REFERENCES:
patent: 4016273 (1977-04-01), Sieger et al.
patent: 4395405 (1983-07-01), Noda et al.
patent: 4530840 (1985-07-01), Tice et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4767628 (1988-08-01), Hutchinson
patent: 4938763 (1990-07-01), Dunn et al.
patent: 5234520 (1993-08-01), McClintock
patent: 5278202 (1994-01-01), Dunn et al.
patent: 5278553 (1994-01-01), Goodey et al.
patent: 5411951 (1995-05-01), Mitchell
patent: 5462863 (1995-10-01), Hsieh et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5589167 (1996-12-01), Cleland et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5728553 (1998-03-01), Goodey et al.
patent: 5747058 (1998-05-01), Tipton et al.
patent: 5889035 (1999-03-01), Strupczewski et al.
patent: 5965386 (1999-10-01), Kerry-Williams et al.
patent: 6004549 (1999-12-01), Reichert et al.
patent: 6015881 (2000-01-01), Kang et al.
patent: 6133418 (2000-10-01), Bolognesi et al.
patent: 6143314 (2000-11-01), Chandrashekar et al.
patent: 6191107 (2001-02-01), Yamagata et al.
patent: 6258782 (2001-07-01), Barney et al.
patent: 6281331 (2001-08-01), Kang et al.
patent: 6328979 (2001-12-01), Yamashita et al.
patent: 6348568 (2002-02-01), Barney et al.
patent: 6475491 (2002-11-01), Johnson et al.
patent: 6541020 (2003-04-01), Ding et al.
patent: 6562787 (2003-05-01), Barney et al.
patent: 6565874 (2003-05-01), Dunn et al.
patent: 6573078 (2003-06-01), Wild et al.
patent: 6630155 (2003-10-01), Chandrashekar et al.
patent: 6656906 (2003-12-01), Barney et al.
patent: 6773714 (2004-08-01), Dunn et al.
patent: 6824783 (2004-11-01), Bolognesi et al.
patent: 6861059 (2005-03-01), Johnson et al.
patent: 6962900 (2005-11-01), Zhou et al.
patent: 6992065 (2006-01-01), Okumu
patent: 7045552 (2006-05-01), Di et al.
patent: 7053209 (2006-05-01), Gibson et al.
patent: 7318931 (2008-01-01), Okumu et al.
patent: 2004/0076602 (2004-04-01), Harris
patent: 2005/0226843 (2005-10-01), Bentley et al.
patent: WO 97/03692 (1997-02-01), None
patent: WO 99/33491 (1999-07-01), None
patent: WO 00/69902 (2000-11-01), None
U.S. Appl. No. 60/214,468, filed Jun. 26, 2000, Jeng & Patel.
Bartus et al., 1998, “Sustained delivery of proteins for novel therapeutic agents.” Science 281:1161-1162.
Coombes et al., 1999, “Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly(ethylene glycol) anchoring segments.” Biomaterials 18(17):1153-1161.
Johnson et al., 1996, “A month-long effect from a single injection of microencapsulated human growth hormone.” Nature Med. 2(7):795-799.
Kilby et al., 1998, “Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.” Nature Med. 4(11):1302-1307.
Kulkarni et al., 1966, “Polylactic acid for surgical implants.” Arch. Surg. 93:839.
Lalezari et al., 2003, “Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.” N. Engl. J. Med :1-10.
Lawless et al., 1996, “HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.” Biochem 35:13697-13708.
Melby et al., 2006, “Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.” AIDS Res & Human Retro. 22(5):375-385.
Middaugh et al., 1979, “Determination of the apparent thermodynamic activities of saturated protein solutions.” J. Biol. Chem. 254(3):367-370.
Middaugh et al., 1992, “Protein Solubility.” Ch. 4 in “Stability of Protein Pharmaceuticals.” Ed.
Otaka et al., 2002, “″Effect of zinc binding and precipitation on structures of recombinant human growth hormone and nerve growth factor” Angewandte Chemie Interantional Ed. 41:2937-2940.
Rusconi et al., 2004, “Entry and fusion inhibitors in HIV.” Expert Opin. Ther. Patients 14(5):733-748.
Sia et al., 2002, “Short constrained peptides that inhibit HIV-1 entry.” Proc. Natl. Acad. Sci. 99:14664-14669.
Sista et al., 2004, “Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.” AIDS 18:1787-1794.
Smith & Tipton, 1996, “A novel parenteral delivery system” Pharma Res. 13(3):300.
Swiderski et al., 1966, “Application of 14C isotope in studies on the lability of sugar substituents” Nukleonika Supl. 10:347-352.
Wild et al., 1994, “Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.” Proc. Natl. Acad. Sci 91:9770-9774.
Yang et al., 2000, “Effect of zinc binding and precipitation on structures of recombinant human growth hormone and nerve growth factor.” J. Pharma Sci 89(11):1480-1485.
Bray Brian L.
Dwyer John
Friedrich Paul E.
Johnston Barbara E.
Schneider Stephen E.
Campell Bruce
Jones Day
Kinsey White Nicole
Trimeris, Inc.
LandOfFree
HIV fusion inhibitor peptides with improved biological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV fusion inhibitor peptides with improved biological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV fusion inhibitor peptides with improved biological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4051163